Feb 18, 2011, 05.01 PM
Hyderabad-based biotechnology company Transgene Biotek plans to raise USD 40 million via global depositary receipt (GDR).
In an exclusive interview with CNBC-TV18's Ekta Batra and Reema Tendulkar, SS Marthi, Director of Transgene Biotek says, "The proposal is to raise USD 40 million via issuance of GDR. A part of this USD 40 million will be utilised for the present product line, which includes oncology drugs, active pharmaceutical ingredients (APIs), oral delivery platform of oral insulin, etc."
Going forward, the company is also looking at certain acquisitions, and, "the proceeds will be utilised for acquisitions as well," he adds.
The company is engaged in sales of medical diagnostic products and services.
Transgene Biote stock price
On February 08, 2016, Transgene Biotek closed at Rs 2.35, down Rs 0.03, or 1.26 percent. The 52-week high of the share was Rs 4.84 and the 52-week low was Rs 1.71.
The latest book value of the company is Rs 23.51 per share. At current value, the price-to-book value of the company was 0.10.
Confident of meeting 10-14% growth guidance: Cognizant India
R Chandrasekaran, Group Chief Executive, Cognizant
Bombay Dyeing Q3 loss widens to Rs 78.15 crore
Its net sales on standalone basis declined by 35.1
Cognizant forecast misses estimates as clients cut IT spending
Cognizant's revenue rose 17.9 percent to USD 3.23
Skill Tree Workplace Excellence: HR practices evolve over time
This week on Skill Tree Workplace Excellence we ge
Science of Spirituality: Understanding the theory of Karma
On the last episode of this series, Science of Spi
Companies Law Committee Report: Hits & Misses
By: Dolphy D’souza, EY